Compare Ecolab Inc. (ECL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Mesoblast Limited — how do they compare? Ecolab Inc. trades at $281.08 (market cap $79.79B), while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: Ecolab Inc. is far larger — about 36.1× Mesoblast Limited's market cap, and Ecolab Inc. pays a 1.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ECL | MESO | |
|---|---|---|
Market Cap | $79.79B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $308.35 | $20.96 |
52-Week Low | $245.73 | $12.88 |
Enterprise Value | $88.57B | $2.21B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $284.4, down slightly (-0.27%) on the day, with a bullish technical signal and strong analyst support (78% buy ratings). The company reported solid Q2 2026 earnings of $2.09 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with 2025 revenue at $16.08B, and profitability remains robust with a net income margin of 12.57%. Recent news highlights institutional activity and the completion of the $4.75B CoolIT acquisition, strengthening its high-tech portfolio.
The outlook is positive, driven by earnings momentum, strategic acquisitions, and a consensus price target of $327.90 implying ~15% upside. Key risks include execution of integration for recent acquisitions, input cost pressures, and broader market volatility. The stock presents a compelling opportunity for growth investors seeking exposure to a stable, dividend-paying company with digital and high-tech expansion drivers.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
